[1] Hypermethylation is linked to methyl-binding proteins, DNA methyltransferases and histone deacetylase, but the degree to which this process selectively silences tumor suppressor genes remains a research area.
[3] Cancer epigenetic silencing in its current state was born in the labs of Baylin and Jones,[3] where it was proven that CpG island hypermethylation was a common inactivation mechanism of the tumor suppressor gene p16INK4a.
The introduction of methylation-specific PCR and sodium bisulfite modification added tools to the belt of cancer epigenetics research,[3][4] and the list of candidate genes with aberrant methylation of their CpG islands has been growing since.
[5] Initially, the presence of alterations in the profile of DNA methylation in cancer was seen as a global hypomethylation of the genome that would lead to massive overexpression of oncogenes with a normally hypermethylated CpG island.
[1] The association of transcriptional silencing of tumor suppressor genes with hypermethylation is the foundation upon which this subset of cancer epigenetics stands.
It is evident that the hypomethylation of the CpG island in normal cells provides no additional steric hindrance to future binding.
The majority of CpG pairs in mammals are chemically modified by the covalent attachment of a methyl group to the C5 position of the cytosine ring.
Colorectal cancer will not necessarily have the same set of hypermethylated CpG islands as in a glioma, and this clinical distinctness of tumors can be interpreted by doctors.
CpG island hypermethylation shows promise for molecular monitoring of patients with cancer, and is also a potential target for therapeutic use.